packageRetifanlimab

retifanlimab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Retifanlimab is a PD-1-blocking monoclonal antibody used to treat cancers, including Merkel cell carcinoma, anal cancer, and squamous cell carcinoma. It is an approved anticancer medicine, with one product authorised in the European Union and other uses still under investigation.

Summary written by glm-5.3-flash from Wikidata Q117349369 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:retifanlimab
ATC codes:L01FF10
DrugBank:DB15766
Wikidata:Q117349369
molar mass:148000 g/mol (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown